The Dow Chemical Company

Dow Global Technolgoies LLC

Eastman-kodak Company

Isotherapeutics Group LLC

Igl Pharma Inc.

Dowell Schlumberger Incorporated

Convergys Cmg Utah Inc.

Convergys Customer Management Group, Inc.

Richard K. Frank

Joseph R. Garlich

David A. Wilson

Jaime Simon

Kenneth Mcmillan

David E. Troutner

David A Wilson

Druce K Crump

R Keith Frank

Joseph R Garlich

Kenneth McMillan

Wynn A Volkert

Phillip S Athey

Steven H Christiansen

Garry E Kiefer

David E Troutner

George M St George

Freddie Griffin, Jr

William F Goeckeler

William Jack Kruper, Jr

Dane Chang

William A Fordyce

Roberta C Cheng

Eric R Brown

Cynthia L Rand

Wayne W Frenier

Michael B Cavitt

Marvin L Dettloff

Alan D Strickland

Lance A Cooper

Wilfred W Wilson

Pierre Thomas Varineau

Jeffrey G Grierson

Bruce Armin Barner

Robert Kirk Thompson

Harrell L Huff

Karen L Musson

Robert J Michalowski

Elizabeth M Stites

Douglas C Weber

Richard Keith Frank

Jennifer M Botts

Aaron W Sanders

Thomas Carl Eisenschmid

Brian W Kolthammer

Walter L Vaughn

Avis L McCrary

Joseph L Deavenport

Richard A Pierce

Matthew D Miller

Stephen B Willis

Jimmy Myers

Kara S Weber

Teresa Littleton

Michael J Johnson

David Bradley Wurm

Katherine H Svatek

Rhonda C Posey

Cameron T Costain

S Bennett Willis

Brian D Burkholder

Dana W Morin

William F Goeckleler

Sharon Braughman

Sharon Baughman

David B Wurn

William F Goeckler

Roy W Schmidt

Kalyan K Ganguli

Gary D Gatton

Jennifer M Boots

Richard K Frank

Bruce A Barner

This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Radioactive compositions and methods for their therapeutic use

This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

High purity therapeutic bone agents

A method to enhance solubility of an active compound comprises combining an active compound, having an aqueous solubility that is less than or equal to about 10 mg/mL, and an amount of methoxypolyethylene glycol that is sufficient to increase the aqueous solubility of the active compound. Enhancement of aqueous solubility for this combination may be significantly greater than that of an active compound in combination with an equivalent amount of polyethylene glycol. Particularly enhanced solubility is shown where a small amount of water is also included. The invention may be used in a wide variety of applications, such as for pharmaceutical, agricultural, antimicrobial, and personal care products.

Method to enhance aqueous solubility of poorly soluble actives

Novel mixtures of long-chain (C10-C20) olefins are functionalized by conversion to aldehydes using an OXO process, or to sulfates, sulfonates, sulfones, sulfides, or sulfoxides by direct sulfonation. The aldehydes may then be hydrogenated to form alcohols, or aminated to form amines or amides. The olefins starting mixture may be acquired as a byproduct of the tetramerization of ethylene in the presence of certain chromium-containing tetramerization catalysts. The functionalized mixtures, and derivatives prepared therefrom such as alkoxylates prepared from the alcohols, may be useful as surfactants that may offer improved performance in many applications, while their preparation based on a byproduct mixture reduces their cost and also reduces waste-handling issues for this non-targeted stream.

Functionalized long-chain olefin mixtures and uses therefor

A chelating composition suitable for low-temperature use or storage is disclosed. The chelating compositions include 20 to 70 wt. percent of a polar solvent and 30 to 80 wt. percent of a first component of the formula: wherein R is a hydroxyalkyl group and each R' is individually selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups, carbonyl-containing alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; R&#x2033; is selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups; carbonyl-substituted alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; Mand Mare alkali metal ions, wherein the Mhas a higher atomic weight than M; wherein x+y=n and the mole fraction of Mis greater than 0.70 to 1. Methods of suppressing crystallization and methods of cleaning surfaces employing the compositions described herein are also disclosed.

Formulations with unexpected cleaning performance incorporating a biodegradable chelant

A chelating composition suitable for low-temperature use or storage is disclosed. The chelating compositions include 20 to 70 wt. percent of a polar solvent and 30 to 80 wt. percent of a first component of the formula: (I) wherein R is a hydroxyalkyl group and each R' is individually selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups, carbonyl-containing alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; R&#x2033; is selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups; carbonyl-substituted alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; Mand Mare alkali metal ions, wherein the Mhas a higher atomic weight than M; wherein x+y=n and the mole fraction of M1 is greater than 0.70 to 1. Methods of suppressing crystallization and methods of cleaning surfaces employing the compositions described herein are also disclosed. 

Compositions and methods for making compositions including a quaternary trialkylammonium halide compound are described. Compositions follow the formula: wherein the Rgroups are each individually selected from alkyl groups having from 1 to 12 carbon atoms; wherein the R, R, and Rgroups are each individually selected from hydrogen, hydroxide, alkyl groups having from 1 to 12 carbon atoms, and hydroxy alkyl groups having from 1 to 12 carbon atoms; wherein y ranges from 0 to 12; wherein Xis selected from fluoride, chloride, bromide, and iodide; wherein the quaternary trialkylammonium compound is present in an amount of at least 90 wt. percent; and wherein the composition comprises not greater than 4000 ppm of a trialkylamine or protonated form thereof.

Process for preparing dihydroxytrialkylammonium halides and products thereof

Polyalkylene glycol compositions having reduced low molecular weight oligomers are disclosed. Some compositions, particularly polyethylene glycol compositions, have a number average molecular weight range from about 3000 to about 10,000 g/mol and have a total oligomer concentration of less than about 400 ppm of all oligomers having a molecular weight of less than or equal to 812 g/mol and a total oligomer concentration of less than about 50 ppm of all oligomers having a molecular weight of less than or equal to 240 g/mol. Other polyalkylene compositions, particularly polyethylene glycol compositions, are characterized by a total oligomer concentration of less than about 90 ppm of all oligomers having a molecular weight less than or equal to 460 g/mol and are obtained without further processing to remove oligomers having a molecular weight of less than about 460 g/mol. Methods for making such compositions are also disclosed.

Reduced oligomer concentration in high purity polyalkylene glycols

Preparation of N-&lsqb;2-(carboxymethoxy) ethyl&rsqb;-N-(carboxymethyl) glycine

A process for preparing polyamino monosuccinic acids, salts or chelates thereof by (a) reacting a maleic or fumaric acid ester or mixtures thereof with a polyamino compound in a primary alcohol as a solvent, (b) hydrolyzing the product obtained in step (a), and (c) separating the primary alcohol. The use of a primary alcohol as the solvent results in a markedly purer polyamino monosuccinic acid product and simpler reaction conditions than when the solvent is a secondary or tertiary alcohol.

Process for the preparation of polyamino succinic acids and derivatives thereof

A stable free-flowing solid chelant composition is produced by the process comprising the steps of: a) adjusting the pH of an aqueous solution of the chelant to a value of from about 1.2 to about 3.0 by the addition of an inorganic acid; and b) drying the pH adjusted aqueous chelant product.

Stable free-flowing solid chelants

An electronic message, or e-mail, management system having a digital computer for accepting e-mail messages; a program interface for automatically transferring received electronic messages to a database; a structured database for storing the received electronic messages in a predetermined format; and an interface for allowing a customer service representative, at a remote computer, to access, and respond to, the electronic messages stored at the database.

Electronic massage management system

Growing community of inventors

Richwood, TX, United States of America

David A Wilson